These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 12070009)

  • 1. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
    Schnittger S; Schoch C; Dugas M; Kern W; Staib P; Wuchter C; Löffler H; Sauerland CM; Serve H; Büchner T; Haferlach T; Hiddemann W
    Blood; 2002 Jul; 100(1):59-66. PubMed ID: 12070009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
    Schnittger S; Schoch C; Kern W; Hiddemann W; Haferlach T
    Acta Haematol; 2004; 112(1-2):68-78. PubMed ID: 15179006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
    Kiyoi H; Naoe T; Nakano Y; Yokota S; Minami S; Miyawaki S; Asou N; Kuriyama K; Jinnai I; Shimazaki C; Akiyama H; Saito K; Oh H; Motoji T; Omoto E; Saito H; Ohno R; Ueda R
    Blood; 1999 May; 93(9):3074-80. PubMed ID: 10216104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication.
    Muñoz L; Aventín A; Villamor N; Juncà J; Acebedo G; Domingo A; Rozman M; Torres JP; Tormo M; Nomdedéu JF
    Haematologica; 2003 Jun; 88(6):637-45. PubMed ID: 12801839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).
    Kainz B; Heintel D; Marculescu R; Schwarzinger I; Sperr W; Le T; Weltermann A; Fonatsch C; Haas OA; Mannhalter C; Lechner K; Jaeger U
    Hematol J; 2002; 3(6):283-9. PubMed ID: 12522450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
    Kottaridis PD; Gale RE; Frew ME; Harrison G; Langabeer SE; Belton AA; Walker H; Wheatley K; Bowen DT; Burnett AK; Goldstone AH; Linch DC
    Blood; 2001 Sep; 98(6):1752-9. PubMed ID: 11535508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.
    Moreno I; Martín G; Bolufer P; Barragán E; Rueda E; Román J; Fernández P; León P; Mena A; Cervera J; Torres A; Sanz MA
    Haematologica; 2003 Jan; 88(1):19-24. PubMed ID: 12551822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
    Fröhling S; Schlenk RF; Breitruck J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K;
    Blood; 2002 Dec; 100(13):4372-80. PubMed ID: 12393388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of FLT3 ITD and D835 mutations in AML patients.
    Sheikhha MH; Awan A; Tobal K; Liu Yin JA
    Hematol J; 2003; 4(1):41-6. PubMed ID: 12692519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.
    Chillón MC; Fernández C; García-Sanz R; Balanzategui A; Ramos F; Fernández-Calvo J; González M; Miguel JF
    Hematol J; 2004; 5(3):239-46. PubMed ID: 15167911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
    Thiede C; Steudel C; Mohr B; Schaich M; Schäkel U; Platzbecker U; Wermke M; Bornhäuser M; Ritter M; Neubauer A; Ehninger G; Illmer T
    Blood; 2002 Jun; 99(12):4326-35. PubMed ID: 12036858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
    Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
    Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.
    Bowen DT; Frew ME; Hills R; Gale RE; Wheatley K; Groves MJ; Langabeer SE; Kottaridis PD; Moorman AV; Burnett AK; Linch DC
    Blood; 2005 Sep; 106(6):2113-9. PubMed ID: 15951308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia.
    Ciolli S; Vannucchi AM; Leoni F; Nozzoli C; Longo G; Salati A; Pancrazzi A; Bianchi L; Gigli F; Bosi A
    Leuk Lymphoma; 2004 Jan; 45(1):73-8. PubMed ID: 15061200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.
    Steudel C; Wermke M; Schaich M; Schäkel U; Illmer T; Ehninger G; Thiede C
    Genes Chromosomes Cancer; 2003 Jul; 37(3):237-51. PubMed ID: 12759922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
    Christiansen DH; Pedersen-Bjergaard J
    Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
    Yanada M; Matsuo K; Suzuki T; Kiyoi H; Naoe T
    Leukemia; 2005 Aug; 19(8):1345-9. PubMed ID: 15959528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
    Zwaan CM; Meshinchi S; Radich JP; Veerman AJ; Huismans DR; Munske L; Podleschny M; Hählen K; Pieters R; Zimmermann M; Reinhardt D; Harbott J; Creutzig U; Kaspers GJ; Griesinger F
    Blood; 2003 Oct; 102(7):2387-94. PubMed ID: 12816873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.